Leonard Schleifer, Regeneron president & CEO, discusses the FDA's approval of its cholesterol-lowering drug Praluent, and concerns over pricing the new drug.» Read More
A Congressional investigation into a recent recall of children’s Tylenol and other pediatric medicines has been stymied by the manufacturer, Johnson & Johnson, investigators say, raising the prospect that new measures — like issuing of subpoenas to compel cooperation — could be invoked.
Thousands of researchers presented studies at the recent cancer forum, but none more significant than those for patients with advanced melanoma.
Powerful protein supplements manufacturers like Muscle Milk and Myoplex were on an incredible trajectory, benefiting strongly from the workout world philosophy that protein building was not only good for energy but for recovery. But a damning Consumer Reports investigation threatens to cripple the burgeoning business that is a big part of the $2.7 billion sports nutrition marketplace.
There is no “quick fix” for cancer, no clear spot of light at the end of the tunnel. This cautious realization is that the fight against cancer is going to take more time than we thought.
Sales of a vaccine for late-stage prostate cancer, Dendreon’s Provenge, are expected to reach $1 billion in the first two years, analysts have predicted. This drug, one of several being showcased at the American Society of Clinical Oncologists meeting, represent a trend in which drugs treat a subgroup of cancer sufferers within the larger disease.
Goodbye, Marlboro Lights. Hello, Marlboro Gold Pack. "Light" cigarettes are going up in smoke by the end of June, but their names and packaging are getting a colorful makeover.
For consumers who turned to drugstore house brands after the recall last month of liquid children’s Tylenol and other medicines made by a unit of Johnson & Johnson, there is yet more unsettling news.
Federal investigators are looking at a farm in Yuma, Ariz., as a possible source of a widespread E. coli outbreak in romaine lettuce, according to the distributor.
A unit of Johnson & Johnson, just months after saying it was phasing out an artificial hip implant because of slowing sales, has warned doctors that the device appears to have a high early failure rate in some patients.
On day five of Avandiagate, GlaxoSmithKline communiques about the brouhaha surrounding the controversial diabetes drug now number six.
Congress could have passed a more sweeping jobs bill with larger bipartisan support if Democrats had been more willing to work with Republicans, Sen. Charles Grassley told CNBC.
The New York Attorney General's office is filing civil charges against Bank of America and its former CEO Ken Lewis, saying the bank misled investors about Merrill Lynch when it acquired the Wall Street bank in late 2008.
For Roche/Genentech the timing could not be worse. At a time when cutting healthcare costs could still end up being put back on the frontburner in Washington comes a study showing how to possibly save a heckuva lot of money.
Johnson & Johnson reported Tuesday better-than-expected fourth quarter sales and earnings, helped by a recovering global economy, but provided a 2010 profit forecast range that barely reached Wall Street projections.
A group of investors in Allen Stanford's alleged Ponzi scheme are demanding a powerful Texas congressman give them the same kind of support he showed Stanford when regulators shut down the alleged scam in February.
A federal judge has denied an emergency request by attorneys for indicted billionaire Allen Stanford to free their client on bail.
Stocks closed higher as a holiday rally got a further push from big technology, banks and commodities, though most investors took Christmas Eve off.
Futures mostly shrugged off news that weekly unemployment claims hit their lowest level in 15 months, but stocks were still poised for a gain in a holiday-shortened session Thursday.
Today starts a two-day FDA public hearing in Washington, DC on biopharma and social media. I decided not to go because talking heads in a meeting room just don't make for good TV. And this is just the first step in what is no doubt going to be a very long, involved policy-making process. But as it turns out, it looks like it might have been futile for me to try to attend anyway.
Disgraced financier Bernard Madoff's longtime auditor has entered a guilty plea in a federal court in Manhattan.